Search

National Society Day 2025

Presentations from the National Society Days held by EHA on February 13 and 14, 2025.

Read more

Committees and units

The EHA Board sets up committees and units to perform specific tasks and activities.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Highlights from the SWG

Standards for functional precision medicine projectStandards for functional precision medicine, a project initiated by EHA's SWG on Precision Hematology, received a 2023 SWG Grant and is currently underway.

Read more

Previous exams

2024 examThe most recent EHA Exam took place on June 13, 2024. In total, 244 candidates took the exam at 15 locations. A further session was organized in Estonia, but did not take place due to an attendance issue.

Read more

Other Useful Resources

Latest EMA publications on COVID-19 vaccines
COVID-19 Vaccine Janssen: update on safety issues
First COVID-19 vaccine approved for children aged 12 to 15 in EU
Insufficient data on use of inhaled corticosteroids to treat COVID-19
EMA issues advice on use of sotrovimab (VIR-7831) for…

Read more